TY  - JOUR
AU  - Porcari, Serena
AU  - Fusco, William
AU  - Spivak, Igor
AU  - Fiorani, Marcello
AU  - Gasbarrini, Antonio
AU  - Elinav, Eran
AU  - Cammarota, Giovanni
AU  - Ianiro, Gianluca
TI  - Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics.
JO  - The lancet / Gastroenterology & Hepatology
VL  - 9
IS  - 5
SN  - 2468-1253
CY  - London
PB  - Elsevier
M1  - DKFZ-2024-00772
SP  - 460 - 475
PY  - 2024
AB  - The gut microbiome is acknowledged as a key determinant of human health, and technological progress in the past two decades has enabled the deciphering of its composition and functions and its role in human disorders. Therefore, manipulation of the gut microbiome has emerged as a promising therapeutic option for communicable and non-communicable disorders. Full exploitation of current therapeutic microbiome modulators (including probiotics, prebiotics, and faecal microbiota transplantation) is hindered by several factors, including poor precision, regulatory and safety issues, and the impossibility of providing reproducible and targeted treatments. Artificial microbiota therapeutics (which include a wide range of products, such as microbiota consortia, bacteriophages, bacterial metabolites, and engineered probiotics) have appeared as an evolution of current microbiota modulators, as they promise safe and reproducible effects, with variable levels of precision via different pathways. We describe the landscape of artificial microbiome therapeutics, from those already on the market to those still in the pipeline, and outline the major challenges for positioning these therapeutics in clinical practice.
KW  - Humans
KW  - Microbiota
KW  - Probiotics: therapeutic use
KW  - Prebiotics
KW  - Gastrointestinal Microbiome
KW  - Fecal Microbiota Transplantation
KW  - Prebiotics (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:38604200
DO  - DOI:10.1016/S2468-1253(23)00357-6
UR  - https://inrepo02.dkfz.de/record/289450
ER  -